Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naive and relapsed/refractory patients with chronic lymphocytic leukemia

被引：0
|
作者：
Andersson, Maria
Mulder, Tom
Heimersson, Kia
Sonnert-Husa, Sonja
Giertz, Annika
Karlsson, Claes
Lundin, Jeanette
Hansson, Lotta
Osterborg, Anders
Palma, Marzia
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553105
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [1] Zanubrutinib, a promising treatment option for treatment-naive patients with chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (05): : 207 - 207
  • [2] Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
    Kater, Arnon P.
    Eichhorst, Barbara F.
    Owen, Carolyn J.
    Jaeger, Ulrich
    Chyla, Brenda
    Lefebure, Marcus
    Millen, Rosemary
    Jiang, Yanwen
    Thadani-Mulero, Maria
    Boyer, Michelle
    Seymour, John F.
    HEMASPHERE, 2024, 8 (08):
  • [3] Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Gulrajani, Michael
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min-Hui
    Byrd, John C.
    CANCER DISCOVERY, 2020, 10 (03) : 394 - 405
  • [4] Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kater, Arnon P.
    Eichhorst, Barbara
    Owen, Carolyn
    Jaeger, Ulrich
    Chyla, Brenda
    Lefebure, Marcus
    Millen, Rosemary
    Jiang, Yanwen
    Thadani-Mulero, Maria
    Seymour, John F.
    BLOOD, 2022, 140 : 7010 - 7012
  • [5] Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
    Cull, Gavin
    Burger, Jan A.
    Opat, Stephen
    Gottlieb, David
    Verner, Emma
    Trotman, Judith
    Marlton, Paula
    Munoz, Javier
    Johnston, Patrick
    Simpson, David
    Stern, Jennifer C.
    Prathikanti, Radha
    Wu, Kenneth
    Novotny, William
    Huang, Jane
    Tam, Constantine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (05) : 1209 - 1218
  • [6] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [7] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [8] Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
    Tam, Constantine S.
    Robak, Tadeusz
    Ghia, Paolo
    Kahl, Brad S.
    Walker, Patricia
    Janowski, Wojciech
    Simpson, David
    Shadman, Mazyar
    Ganly, Peter S.
    Laurenti, Luca
    Opat, Stephen
    Tani, Monica
    Ciepluch, Hanna
    Verner, Emma
    Simkovi, Martin
    Osterborg, Anders
    Trneny, Marek
    Tedeschi, Alessandra
    Paik, Jason C.
    Kuwahara, Sowmya B.
    Feng, Shibao
    Ramakrishnan, Vanitha
    Cohen, Aileen
    Huang, Jane
    Hillmen, Peter
    Brown, Jennifer R.
    HAEMATOLOGICA, 2021, 106 (09) : 2354 - 2363
  • [9] BUDGET IMPACT OF ZANUBRUTINIB FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Xiao, Y.
    Gani, R.
    Xue, M.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (12) : S65 - S66
  • [10] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB FOR PATIENTS WITH TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Xiao, Y.
    Gani, R.
    Xue, M.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (12) : S120 - S120
12345